Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 8/2015

01-08-2015 | Editorial

Overdiagnosis of osteoporosis: fact or fallacy?

Author: J. Compston

Published in: Osteoporosis International | Issue 8/2015

Login to get access

Excerpt

In their paper in the British Medical Journal, “Overdiagnosis of bone fragility in the quest to prevent hip fracture”, Järvinen et al. claim that there is inadequate evidence to support current pharmacological approaches to the prevention of hip fracture [1]. They state, correctly, that the vast majority of hip fractures follow a fall but fail to recognize the obvious connection between the consequence of a fall and bone strength. With the use of selective and misleading presentation of published evidence, they provide a biased critique of current strategies for risk assessment and prevention of hip fracture. Most surprisingly, they fail even to mention Fracture Liaison Services, a model of care that has been shown to be both effective and cost-effective in the secondary prevention of fracture and has been successfully adopted in many parts of the world [2‐7]. …
Literature
1.
Järvinen TL, Michaëlsson K, Jokihaara J, Collins GS, Perry TL, Mintzes B et al (2015) Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 350:h2088PubMedCrossRef
2.
Sander B, Elliot-Gibson V, Beaton DE, Bogoch ER, Maetzel A (2008) A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs. J Bone Joint Surg Am 90:1197–1205PubMedCrossRef
3.
Majumdar SR, Lier DA, Beaupre LA, Hanley DA, Maksymowych WP et al (2009) Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med 169:25–31PubMedCrossRef
4.
Greene D, Dell RM (2010) Outcomes of an osteoporosis disease-management program managed by nurse practitioners. J Am Acad Nurse Pract 22:326–329PubMedCrossRef
5.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L et al (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRef
6.
Cooper MS, Palmer AJ, Seibel MJ (2012) Cost-effectiveness of the concord minimal trauma fracture liaison service, a prospective, controlled fracture prevention study. Osteoporos Int 23:97–107PubMedCrossRef
7.
Solomon DH, Patrick AR, Schousboe J, Losina E (2014) The potential economic benefits of improved post-fracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system. J Bone Miner Res 29:1667–1674PubMedCentralPubMedCrossRef
8.
Liu SK, Munson JC, Bell JE, Zaha RL, Mecchella JN, Tosteson AN et al (2013) Quality of osteoporosis care of older Medicare recipients with fragility fractures: 2006 to 2010. J Am Geriatr Soc 61:1855–1862PubMedCentralPubMedCrossRef
9.
Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29:1926–1928PubMedCrossRef
10.
11.
Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995PubMedCrossRef
12.
Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Osteoporotic Fractures Research Group et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947–1954PubMedCrossRef
13.
14.
15.
16.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57PubMedCentralPubMedCrossRef
17.
18.
Silva RB, Eslick GD, Duque G (2013) Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis. J Am Med Dir Assoc 14:685–689PubMedCrossRef
19.
Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM et al (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 9:CD007146PubMed
20.
El-Khoury F, Cassou B, Charles MA, Dargent-Molina P (2013) The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. BMJ 347:f6234PubMedCentralPubMedCrossRef
21.
Black D, Cummings S, Karpf D, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMedCrossRef
22.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRef
23.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef
24.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, FREEDOM Trial et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef
25.
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, HORIZON Pivotal Fracture Trial et al (2009) Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94:3215–3225PubMedCrossRef
26.
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, for the HORIZON Recurrent Fracture Trial et al (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967PubMedCentralPubMedCrossRef
27.
Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM (2015) Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 175:913–921PubMedCrossRef
28.
Roux C, Wyman A, Hooven FH, Gehlbach SH, Adachi JD, Chapurlat RD, GLOW investigators et al (2012) Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int 23:2863–2871PubMedCrossRef
29.
Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832–1839PubMedCrossRef
30.
Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, FIT Research Group et al (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20:971–976PubMedCrossRef
31.
Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292–299PubMedCentralPubMedCrossRef
32.
Kanis JA, Hiligsmann M (2014) The application of health technology assessment in osteoporosis. Best Pract Res Clin Endocrinol Metab 28:895–910PubMedCrossRef
33.
Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY et al (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33:205–224PubMedCrossRef
Metadata
Title
Overdiagnosis of osteoporosis: fact or fallacy?
Author
J. Compston
Publication date
01-08-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3220-0

Other articles of this Issue 8/2015

Osteoporosis International 8/2015 Go to the issue

Original Article

The relationship of thoracic kyphosis to gait performance and quality of life in women with osteoporosis

Position Paper

FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK

Original Article

Exercise capacity independently predicts bone mineral density and proximal femoral geometry in patients with acute decompensated heart failure

Original Article

Serum 25-hydroxyvitamin D level and risk of falls in Japanese community-dwelling elderly women: a 1-year follow-up study

Original Article

Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™

Original Article

Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures